Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1988 Jan;56(1):45–50. doi: 10.1128/iai.56.1.45-50.1988

Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Y Iizawa 1, T Nishi 1, M Kondo 1, K Tsuchiya 1, A Imada 1
PMCID: PMC259231  PMID: 3275585

Abstract

The effect of recombinant human interleukin-2 (rIL-2) on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice was examined. rIL-2 was administered subcutaneously once a day for 7 or 14 days, starting 2 weeks after the mice were infected. Administration of 2 or 20 micrograms of rIL-2 per mouse daily for 7 days reduced bacterial counts in the lungs dose dependently. At a dose of 0.2 microgram per day, proliferation of bacteria in the lungs was suppressed after 14 days of administration. Agglutinin titers in serum were not affected by rIL-2 treatment. Monocyte and lymphocyte counts in peripheral blood were increased by administration of 20 micrograms of rIL-2 daily for 14 days but not by treatment for 7 days. In addition, clearance of bacteria from the lungs after aerosol exposure was enhanced by treatment for 7 days before infection. Thus, rIL-2 acted therapeutically or prophylactically in the presence or absence, respectively, of a specific antigen. These effects were not abolished by anti-asialo GM1 antibody. This suggests that activation of natural killer cells does not play a critical role in the therapeutic and prophylactic effects of rIL-2.

Full text

PDF
45

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chong K. T. Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria. Infect Immun. 1987 Mar;55(3):668–673. doi: 10.1128/iai.55.3.668-673.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Choromanski L., Kuhn R. E. Interleukin 2 enhances specific and nonspecific immune responses in experimental Chagas' disease. Infect Immun. 1985 Nov;50(2):354–357. doi: 10.1128/iai.50.2.354-357.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Colizzi V., Ferluga J., Garreau F., Malkovsky M., Asherson G. L. Suppressor cells induced by BCG release non-specific factors in vitro which inhibit DNA synthesis and interleukin-2 production. Immunology. 1984 Jan;51(1):65–71. [PMC free article] [PubMed] [Google Scholar]
  4. Deepe G. S., Jr, Taylor C. L., Harris J. E., Bullock W. E. Modulation of cellular immune responses in mice with disseminated histoplasmosis by recombinant interleukin-2. Infect Immun. 1986 Jul;53(1):6–12. doi: 10.1128/iai.53.1.6-12.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Deschenes M., Guenounou M., Ronco E., Vacheron F., Nauciel C. Impairment of lymphocyte proliferative responses and interleukin-2 production in susceptible (C57BL/6) mice infected with Salmonella typhimurium. Immunology. 1986 Jun;58(2):225–230. [PMC free article] [PubMed] [Google Scholar]
  6. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  7. Fowles R. E., Fajardo I. M., Leibowitch J. L., David J. R. The enhancement of macrophage bacteriostasis by products of activated lymphocytes. J Exp Med. 1973 Oct 1;138(4):952–964. doi: 10.1084/jem.138.4.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fukutome T., Mitsuyama M., Takeya K., Nomoto K. Importance of antiserum and phagocytic cells in the protection of mice against infection by Klebsiella pneumoniae. J Gen Microbiol. 1980 Jul;119(1):225–229. doi: 10.1099/00221287-119-1-225. [DOI] [PubMed] [Google Scholar]
  9. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harel-Bellan A., Joskowicz M., Fradelizi D., Eisen H. Modification of T-cell proliferation and interleukin 2 production in mice infected with Trypanosoma cruzi. Proc Natl Acad Sci U S A. 1983 Jun;80(11):3466–3469. doi: 10.1073/pnas.80.11.3466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hefeneider S. H., Conlon P. J., Henney C. S., Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol. 1983 Jan;130(1):222–227. [PubMed] [Google Scholar]
  12. Henney C. S., Kuribayashi K., Kern D. E., Gillis S. Interleukin-2 augments natural killer cell activity. Nature. 1981 May 28;291(5813):335–338. doi: 10.1038/291335a0. [DOI] [PubMed] [Google Scholar]
  13. Hinuma S., Naruo K., Ootsu K., Houkan T., Shiho O., Tsukamoto K. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells. Immunology. 1987 Feb;60(2):173–179. [PMC free article] [PubMed] [Google Scholar]
  14. Hinuma S., Naruo K., Shiho O., Tsukamoto K. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2. Immunology. 1986 Oct;59(2):251–259. [PMC free article] [PubMed] [Google Scholar]
  15. Hinuma S., Onda H., Naruo K., Ichimori Y., Koyama M., Tsukamoto K. Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun. 1982 Nov 30;109(2):363–369. doi: 10.1016/0006-291x(82)91729-6. [DOI] [PubMed] [Google Scholar]
  16. Hoffenbach A., Lagrange P. H., Bach M. A. Deficit of interleukin 2 production associated with impaired T-cell proliferative responses in Mycobacterium lepraemurium infection. Infect Immun. 1983 Jan;39(1):109–116. doi: 10.1128/iai.39.1.109-116.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kato K., Naruo K., Koyama M., Kawahara K., Hinuma S., Tada H., Sugino H., Tsukamoto K. Purification and partial sequence analysis of human interleukin-2 derived from peripheral blood leukocytes. Biochem Biophys Res Commun. 1985 Feb 28;127(1):182–190. doi: 10.1016/s0006-291x(85)80142-x. [DOI] [PubMed] [Google Scholar]
  18. Kato K., Yamada T., Kawahara K., Onda H., Asano T., Sugino H., Kakinuma A. Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli. Biochem Biophys Res Commun. 1985 Jul 31;130(2):692–699. doi: 10.1016/0006-291x(85)90472-3. [DOI] [PubMed] [Google Scholar]
  19. Lelchuk R., Rose G., Playfair J. H. Changes in the capacity of macrophages and T cells to produce interleukins during murine malaria infection. Cell Immunol. 1984 Apr 1;84(2):253–263. doi: 10.1016/0008-8749(84)90097-2. [DOI] [PubMed] [Google Scholar]
  20. Lowenthal J. W., Zubler R. H., Nabholz M., MacDonald H. R. Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. Nature. 1985 Jun 20;315(6021):669–672. doi: 10.1038/315669a0. [DOI] [PubMed] [Google Scholar]
  21. Malkovský M., Loveland B., North M., Asherson G. L., Gao L., Ward P., Fiers W. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature. 1987 Jan 15;325(6101):262–265. doi: 10.1038/325262a0. [DOI] [PubMed] [Google Scholar]
  22. Markham R. B., Goellner J., Pier G. B. In vitro T cell-mediated killing of Pseudomonas aeruginosa. I. Evidence that a lymphokine mediates killing. J Immunol. 1984 Aug;133(2):962–968. [PubMed] [Google Scholar]
  23. Naruo K., Hinuma S., Kato K., Koyama M., Tada H., Shiho O., Tsukamoto K. Comparison of the biological properties of purified natural and recombinant human interleukin-2. Biochem Biophys Res Commun. 1985 Apr 16;128(1):257–264. doi: 10.1016/0006-291x(85)91672-9. [DOI] [PubMed] [Google Scholar]
  24. Nathan C. F., Murray H. W., Wiebe M. E., Rubin B. Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983 Sep 1;158(3):670–689. doi: 10.1084/jem.158.3.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nishi T., Tsuchiya K. Experimental respiratory tract infection with Klebsiella pneumoniae DT-S in mice: chemotherapy with kanamycin. Antimicrob Agents Chemother. 1980 Mar;17(3):494–505. doi: 10.1128/aac.17.3.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Nishi T., Tsuchiya K. Experimental urinary tract infection with Pseudomonas aeruginosa in mice. Infect Immun. 1978 Nov;22(2):508–515. doi: 10.1128/iai.22.2.508-515.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pennington J. E., Rossing T. H., Boerth L. W., Lee T. H. Isolation and partial characterization of a human alveolar macrophage-derived neutrophil-activating factor. J Clin Invest. 1985 Apr;75(4):1230–1237. doi: 10.1172/JCI111820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pennington J. E., Rossing T. H., Boerth L. W. The effect of human alveolar macrophages on the bactericidal capacity of neutrophils. J Infect Dis. 1983 Jul;148(1):101–109. doi: 10.1093/infdis/148.1.101. [DOI] [PubMed] [Google Scholar]
  29. Perussia B., Dayton E. T., Fanning V., Thiagarajan P., Hoxie J., Trinchieri G. Immune interferon and leukocyte-conditioned medium induce normal and leukemic myeloid cells to differentiate along the monocytic pathway. J Exp Med. 1983 Dec 1;158(6):2058–2080. doi: 10.1084/jem.158.6.2058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Reiner N. E., Finke J. H. Interleukin 2 deficiency in murine Leishmaniasis donovani and its relationship to depressed spleen cell responses to phytohemagglutinin. J Immunol. 1983 Sep;131(3):1487–1491. [PubMed] [Google Scholar]
  31. Romagnani S., Del Prete G., Giudizi M. G., Biagiotti R., Almerigogna F., Tiri A., Alessi A., Mazzetti M., Ricci M. Direct induction of human B-cell differentiation by recombinant interleukin-2. Immunology. 1986 May;58(1):31–35. [PMC free article] [PubMed] [Google Scholar]
  32. Sharma S. D., Hofflin J. M., Remington J. S. In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol. 1985 Dec;135(6):4160–4163. [PubMed] [Google Scholar]
  33. Shaw J., Monticone V., Mills G., Paetkau V. Effects of costimulator on immune responses in vitro. J Immunol. 1978 Jun;120(6):1974–1980. [PubMed] [Google Scholar]
  34. Smith K. A. Interleukin 2. Annu Rev Immunol. 1984;2:319–333. doi: 10.1146/annurev.iy.02.040184.001535. [DOI] [PubMed] [Google Scholar]
  35. Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., Hamuro J. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983 Mar 24;302(5906):305–310. doi: 10.1038/302305a0. [DOI] [PubMed] [Google Scholar]
  36. Yamada T., Kato K., Kawahara K., Nishimura O. Separation of recombinant human interleukin-2 and methionyl interleukin-2 produced in Escherichia coli. Biochem Biophys Res Commun. 1986 Mar 28;135(3):837–843. doi: 10.1016/0006-291x(86)91004-1. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES